EG-VEGF nucleic acids and polypeptides and methods of use

Details EG-VEGF nucleic acids and polypeptides and methods of use EG-VEGF nucleic acids and polypeptides and methods of use

2011-06-14

2011-06-14

Belyavskyi, Michail A (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S069100, C435S455000

Reexamination Certificate

active

07960531

ABSTRACT:
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.

REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6485938 (2002-11-01), Sheppard et al.
patent: 7119177 (2006-10-01), Goddard et al.
patent: 7189814 (2007-03-01), Goddard et al.
patent: 7264801 (2007-09-01), Ferrara et al.
patent: 7446168 (2008-11-01), Ferrara et al.
patent: 7727536 (2010-06-01), Ferrara et al.
patent: 7736645 (2010-06-01), Ferrara et al.
patent: 2002/0172678 (2002-11-01), Ferrara et al.
patent: 2010/0254999 (2010-10-01), Ferrara et al.
patent: 2010/0256226 (2010-10-01), Ferrara et al.
patent: 0 843 563 (1998-04-01), None
patent: 1 033 401 (2000-09-01), None
patent: 0 607 054 (2002-11-01), None
patent: WO 97/07198 (1997-02-01), None
patent: WO 98/39448 (1998-09-01), None
patent: WO 98/42741 (1998-10-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 00/53753 (1999-09-01), None
patent: WO 99/46375 (1999-09-01), None
patent: WO 99/53040 (1999-10-01), None
patent: WO 99/63083 (1999-12-01), None
patent: WO 99/63088 (1999-12-01), None
patent: WO 00/08145 (2000-02-01), None
patent: WO 00/52022 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 00/73454 (2000-12-01), None
patent: WO 00/75327 (2000-12-01), None
patent: WO 01/36465 (2001-05-01), None
patent: WO 01/40466 (2001-06-01), None
patent: WO 01/57190 (2001-08-01), None
Abaza et al., 1992, “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin.” J Protein Chem. 11(5):433-444.
Aird et al., I997,“Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment”. Cell Bio. 138:1117-1124.
Aravind & Koonen., 1998, “A colipase fold in the carboxy-terminal domain of the Wnt antagonists—the Dickkopfs” Curr Biol., 8:477-478.
Arbiser et al., 1997, “Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways” Proc. Natl. Acad. Sci. USA, 94:861-866.
Attwood et al., 2000, “The babel of bioinformatics.” Science 290(5491):417-473.
Barrios et al., 2004, “Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor.” J Molec. Recognition 17:332-338.
Basset, D.L., 1943, “The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle” Am. J. Anat., 73:251-278.
Boisbouvier et al., 1998, “A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis” J. Mol. Biol. 283: 205-219.
Bowie et al., 1999, “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” Science, 247(247): 1306-1310.
Brandon, 1985, “Improved Immunocytochemical Straining Through the Use of Fab Fragments of Primary Antibody, Fab-specific Second Antibody, and Fab-Horseradish Peroxidase.” J. of Histochem. & Cytochem. 33(7): 715-719715-719.
Brekken et al., 1998, “Vascular endothelial growth factor as a marker of tumor endothelium.” Cancer Res 58(9):1952-59.
Bullock et al., 2004, “Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists” Mol. Pharmacol. 65:582-588.
Carmeliet et al., 2001, “Cardiovascular biology. Creating unique blood vessels.” Nature 412:868-869.
Carmeliet, P., 2000, “Mechanisms of angiogenesis and arteriogenesis” Nature Medicine. 6:389-395.
Collin, O. & Bergh, A. 1996,“Leydig cells secrete factors which increase vascular permeability and endothelial cell proliferation” Int. J. Androl., 19:221-228.
Dellian, M. et al., 1996, “Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment” Am. J. Pathology, 149:59-71.
Dermer, Gerald B. 1994, “Another anniversary for the war on cancer,” Bio/Technology, 12:320.
Esser, S. et al., 1998. “Vascular endothelial growth factor induces endothelial fenestrations in vitro” J. Cell. Biol., 140:947-959.
Ferrara et al., 2004, “EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors.” Biochim Biophys acta 1654(1):69-78.
Ferrara, N. & Alitalo, 1999, “K. Clinical applications of angiogenic growth factors and their inhibitors” Nature Medicine, 5:1359-1364.
Ferrara, N. et al.. 1998, “Vascular endothelial growth factor is essential for corpus luteum angiogenesis” Nature Medicine, 4:336-340.
Ferrara, N., 2000, “VEGF: an update on biological and therapeutic aspects” Curr. Opin. Biotech 11: 617-624.
Fogarty, M et al 2002, “Information overload,” The Scientist, 2002, 16(16):16.
Fraser et al., 2000, “Suppression of Luteal Angiogenesis in the Primate after Neutralization of Vascular Endothelial Growth Factor” Endocrinology, 141(3):995-1000.
GENBANK Blast results A1-A42: Sequence Identity comparison of: P—AAC84469, P—AAF44237, P—AAC97496, P—AAS21478, P—AAZ65091, AX056658, P—AAC84303, AX048197, P—AAF85370, AX146968, P—AAA75155, P—AAA75177, P—AAA75176, P—AAA75175, and AF333024, dated Nov. 21, 2001.
GENBANK Blast results B1-B5 Sequence Identity comparison of P—AAB53096, P—AAB48067, P—AAB65268, P—AAB48175, P—AAB70148, P—AAB68427, P—AAU12406, P—AAY66745, P—AAB18453, CAC41157.1, NP—115790.1. PRK1—HUMAN, P—AAB70147, P—AAM79066, P—AAB18475, P—AAB18474, P—AAB18473, P—AAB70146, P—AAB70145, dated Nov. 21, 2001.
Gille, H, et al., 2001, “Analysis of biological effects and signaling properties of Flt-1(VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants” J. Biol. Chem., 276:3222-3230.
Glinka, A. et al., 1998, “Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction” Nature, 391 :357-362.
Goldziher, J.W. & Green, J.A.., 1962, “The polycystic ovary. I. Clinical and histologic features” J. Clin. Endocrinol. Meta. 22:325-332.
Gospodarowitcz et al., 1984 “Comparison of the Ability of Basement Membranes Produced by Corneal Endothelial and Mouse-derived Endodermal PF-HR-9 Cells to Support the Proliferation and Differentiation of Bovine Kidney Tubule Epithelial Cells in Vitro”, J. Cell. Biol., 99:947-961.
Gura et al., 1997, “Systems for identifying new drugs are often faulty.” Science 278:1041-1042.
Harlow et al., 1988, Antibodies—A Laboratory manual, Cold Spring Harbor laboratory production, Cold Spring Harbor, NY pp. 626-629.
Herberman et al., 2006, “Cancer chemoprevention and cancer preventive vaccines—a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgen

Affiliated with

Also associated with

Rating

EG-VEGF nucleic acids and polypeptides and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with EG-VEGF nucleic acids and polypeptides and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EG-VEGF nucleic acids and polypeptides and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2629402